These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 24472091)

  • 1. Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic.
    Toresen KH; Salte IM; Skrede S; Nilsen RM; Leiva RA
    Scand J Gastroenterol; 2014 Apr; 49(4):465-72. PubMed ID: 24472091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
    Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
    Mehta SH; Lucas GM; Mirel LB; Torbenson M; Higgins Y; Moore RD; Thomas DL; Sulkowski MS
    AIDS; 2006 Nov; 20(18):2361-9. PubMed ID: 17117023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection.
    Hanouneh IA; Feldstein AE; Lopez R; Yerian L; Pillai A; Zein CO; Zein NN
    Clin Gastroenterol Hepatol; 2008 May; 6(5):584-9. PubMed ID: 18455698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
    Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
    Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
    Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
    J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of liver disease in Korea: hepatitis C.
    Lim YS
    Korean J Hepatol; 2009 Dec; 15 Suppl 6():S25-8. PubMed ID: 20037276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
    Saad Y; Ahmed A; Saleh DA; Doss W
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.
    Gramenzi A; Conti F; Cammà C; Grieco A; Picciotto A; Furlan C; Romagno D; Costa P; Rendina M; Ancarani F; Chiaramonte M; Verucchi G; Craxì A; Bernardi M; Andreone P;
    Dig Liver Dis; 2012 Aug; 44(8):674-80. PubMed ID: 22538206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.
    Kelly EM; Cooper CL
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1177-82. PubMed ID: 23652916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of a Hepatitis C screening program at a large urban VA medical center.
    Groom H; Dieperink E; Nelson DB; Garrard J; Johnson JR; Ewing SL; Stockley H; Durfee J; Jonk Y; Willenbring ML; Ho SB
    J Clin Gastroenterol; 2008 Jan; 42(1):97-106. PubMed ID: 18097298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan.
    McDonald SA; Hutchinson SJ; Innes HA; Allen S; Bramley P; Bhattacharyya D; Carman W; Dillon JF; Fox R; Fraser A; Goldberg DJ; Kennedy N; Mills PR; Morris J; Stanley AJ; Wilks D; Hayes PC
    J Viral Hepat; 2014 May; 21(5):366-76. PubMed ID: 24716639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving access to care by allowing self-referral to a hepatitis C clinic.
    Doucette KE; Robson V; Shafran S; Kunimoto D
    Can J Gastroenterol; 2009 Jun; 23(6):421-4. PubMed ID: 19543572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital.
    Yan KK; Wong GL; Wong VW; Chan HL
    Dig Dis Sci; 2010 Dec; 55(12):3541-7. PubMed ID: 20927593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.
    Knott A; Dieperink E; Willenbring ML; Heit S; Durfee JM; Wingert M; Johnson JR; Thuras P; Ho SB
    Am J Gastroenterol; 2006 Oct; 101(10):2254-62. PubMed ID: 17032190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.